These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37305209)

  • 21. Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors.
    McAulay K; Hoyt EA; Thomas M; Schimpl M; Bodnarchuk MS; Lewis HJ; Barratt D; Bhavsar D; Robinson DM; Deery MJ; Ogg DJ; Bernardes GJL; Ward RA; Waring MJ; Kettle JG
    J Am Chem Soc; 2020 Jun; 142(23):10358-10372. PubMed ID: 32412754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New drug design with covalent modifiers.
    Adeniyi AA; Muthusamy R; Soliman ME
    Expert Opin Drug Discov; 2016; 11(1):79-90. PubMed ID: 26757171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery.
    Zhao Z; Bourne PE
    Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy.
    Yuan M; Chu Y; Duan Y
    Front Chem; 2021; 9():691093. PubMed ID: 34291036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling covalent-modifier drugs.
    Awoonor-Williams E; Walsh AG; Rowley CN
    Biochim Biophys Acta Proteins Proteom; 2017 Nov; 1865(11 Pt B):1664-1675. PubMed ID: 28528876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug discovery for a new generation of covalent drugs.
    Kalgutkar AS; Dalvie DK
    Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterising covalent warhead reactivity.
    Martin JS; MacKenzie CJ; Fletcher D; Gilbert IH
    Bioorg Med Chem; 2019 May; 27(10):2066-2074. PubMed ID: 30975501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
    Ábrányi-Balogh P; Petri L; Imre T; Szijj P; Scarpino A; Hrast M; Mitrović A; Fonovič UP; Németh K; Barreteau H; Roper DI; Horváti K; Ferenczy GG; Kos J; Ilaš J; Gobec S; Keserű GM
    Eur J Med Chem; 2018 Dec; 160():94-107. PubMed ID: 30321804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Research progress of the small molecule covalent inhibitors].
    Yang B; Wang WJ; Li LL
    Yao Xue Xue Bao; 2014 Feb; 49(2):158-65. PubMed ID: 24761604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent peptides and proteins for therapeutics.
    Berdan VY; Klauser PC; Wang L
    Bioorg Med Chem; 2021 Jan; 29():115896. PubMed ID: 33285408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and application of novel electrophilic warheads in target identification and drug discovery.
    Liu Y; Lv S; Peng L; Xie C; Gao L; Sun H; Lin L; Ding K; Li Z
    Biochem Pharmacol; 2021 Aug; 190():114636. PubMed ID: 34062128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.
    Brogi S; Ibba R; Rossi S; Butini S; Calderone V; Gemma S; Campiani G
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.
    Akçay G; Belmonte MA; Aquila B; Chuaqui C; Hird AW; Lamb ML; Rawlins PB; Su N; Tentarelli S; Grimster NP; Su Q
    Nat Chem Biol; 2016 Nov; 12(11):931-936. PubMed ID: 27595327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
    Ma Y; Li L; He S; Shang C; Sun Y; Liu N; Meek TD; Wang Y; Shang L
    J Med Chem; 2019 Jul; 62(13):6146-6162. PubMed ID: 31184893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting biomolecules with reversible covalent chemistry.
    Bandyopadhyay A; Gao J
    Curr Opin Chem Biol; 2016 Oct; 34():110-116. PubMed ID: 27599186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
    Kumalo HM; Bhakat S; Soliman ME
    Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.
    Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M
    Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysine-Targeting Covalent Inhibitors.
    Pettinger J; Jones K; Cheeseman MD
    Angew Chem Int Ed Engl; 2017 Nov; 56(48):15200-15209. PubMed ID: 28853194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.